| pubmed-article:17516241 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17516241 | lifeskim:mentions | umls-concept:C1134719 | lld:lifeskim |
| pubmed-article:17516241 | lifeskim:mentions | umls-concept:C0205617 | lld:lifeskim |
| pubmed-article:17516241 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:17516241 | lifeskim:mentions | umls-concept:C1415278 | lld:lifeskim |
| pubmed-article:17516241 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:17516241 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:17516241 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17516241 | pubmed:dateCreated | 2007-5-22 | lld:pubmed |
| pubmed-article:17516241 | pubmed:abstractText | Phospholipid Hydroperoxide Glutathione Peroxidase (PHGPx) is the only known enzyme able to reduce lipid peroxides bound to cell membranes. Moreover it has been involved in apoptosis and can influence intracellular signaling. To investigate the possible relationship between PHGPx and human cancer we have quantified PHGPx expression levels by real-time quantitative PCR and immunohistochemistry in tissue samples of human breast invasive ductal carcinoma from 34 patients compared with their own controls of benign breast tissue. PHGPx expression levels were compared with the clinical and pathological data of these patients. The results showed that PHGPx expression levels are downregulated in poorly differentiated (grade 3) breast invasive ductal carcinoma (P = 0.0043). PHGPx expression levels decreased gradually with tumor grade from grade 1 to grade 3. We also found a downregulation of PHGPx in cases that showed p53 accumulation compared with cases without p53 immunostaining (P = 0.0011). PHGPx was also downregulated in cases without progesterone receptors (PR) immunostaining compared with cases with PR immunostaining (P = 0.0165). Grade 3, p53 immunostaining and absence of PR immunostaining are poor prognostic factors. These results suggest that PHGPx downregulation could be related with a poorer prognosis in breast invasive ductal carcinoma. | lld:pubmed |
| pubmed-article:17516241 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17516241 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17516241 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17516241 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17516241 | pubmed:issn | 1071-5762 | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:EspinosaEE | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:De CastroJJ | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:RenartJJ | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:RedondoAA | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:CasadoEE | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:FeliuJJ | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:ZamoraPP | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:González-Baró... | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:BarriusoJJ | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:SerenoMM | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:CejasPP | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:García-Cabeza... | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:Belda-Iniesta... | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:FresnoJ AJA | lld:pubmed |
| pubmed-article:17516241 | pubmed:author | pubmed-author:HardissonD... | lld:pubmed |
| pubmed-article:17516241 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17516241 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:17516241 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17516241 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17516241 | pubmed:pagination | 681-7 | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:meshHeading | pubmed-meshheading:17516241... | lld:pubmed |
| pubmed-article:17516241 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17516241 | pubmed:articleTitle | Phospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma. | lld:pubmed |
| pubmed-article:17516241 | pubmed:affiliation | Medical Oncology Service, Hospital Universitario La Paz, Madrid, Spain. | lld:pubmed |
| pubmed-article:17516241 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:2879 | entrezgene:pubmed | pubmed-article:17516241 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17516241 | lld:entrezgene |
